Angiogenesis Completed Phase 2 Trials for Lenalidomide (DB00480)

IndicationStatusPhase
DBCOND0036757 (Angiogenesis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00744536Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDSTreatment